These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8749736)
21. Iron-oxide labeling of hematogenous macrophages in a model of experimental autoimmune encephalomyelitis and the contribution to signal loss in fast imaging employing steady state acquisition (FIESTA) images. Oweida AJ; Dunn EA; Karlik SJ; Dekaban GA; Foster PJ J Magn Reson Imaging; 2007 Jul; 26(1):144-51. PubMed ID: 17659552 [TBL] [Abstract][Full Text] [Related]
22. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. Enochs WS; Harsh G; Hochberg F; Weissleder R J Magn Reson Imaging; 1999 Feb; 9(2):228-32. PubMed ID: 10077018 [TBL] [Abstract][Full Text] [Related]
23. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging. Müller K; Skepper JN; Tang TY; Graves MJ; Patterson AJ; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983 [TBL] [Abstract][Full Text] [Related]
24. Quantitative renal cortical perfusion in human subjects with magnetic resonance imaging using iron-oxide nanoparticles: influence of T1 shortening. Morell A; Ahlstrom H; Schoenberg SO; Abildgaard A; Bock M; Bjørnerud A Acta Radiol; 2008 Oct; 49(8):955-62. PubMed ID: 18615336 [TBL] [Abstract][Full Text] [Related]
25. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. Arbab AS; Wilson LB; Ashari P; Jordan EK; Lewis BK; Frank JA NMR Biomed; 2005 Oct; 18(6):383-9. PubMed ID: 16013087 [TBL] [Abstract][Full Text] [Related]
26. Alterations in hepatic uptake and distribution of organ-specific superparamagnetic MRI contrast media: clinical findings and classification according to pathogenesis. Macarini L; Marini S; Murrone M; Ettorre GC Radiol Med; 2004; 108(1-2):92-106. PubMed ID: 15269693 [TBL] [Abstract][Full Text] [Related]
27. Assessment of T1 and T2* effects in vivo and ex vivo using iron oxide nanoparticles in steady state--dependence on blood volume and water exchange. Bjørnerud A; Johansson LO; Briley-Saebø K; Ahlström HK Magn Reson Med; 2002 Mar; 47(3):461-71. PubMed ID: 11870832 [TBL] [Abstract][Full Text] [Related]
28. Superparamagnetic nanoparticles as blood-pool contrast agents. Contribution to MRI preclinical investigations. Benderbous S; Bonnemain B Radiologe; 1995 Nov; 35(11 Suppl 2):S248-52. PubMed ID: 8588030 [No Abstract] [Full Text] [Related]
29. Transferrin receptor upregulation: in vitro labeling of rat mesenchymal stem cells with superparamagnetic iron oxide. Schäfer R; Kehlbach R; Wiskirchen J; Bantleon R; Pintaske J; Brehm BR; Gerber A; Wolburg H; Claussen CD; Northoff H Radiology; 2007 Aug; 244(2):514-23. PubMed ID: 17562811 [TBL] [Abstract][Full Text] [Related]
30. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Okon E; Pouliquen D; Okon P; Kovaleva ZV; Stepanova TP; Lavit SG; Kudryavtsev BN; Jallet P Lab Invest; 1994 Dec; 71(6):895-903. PubMed ID: 7807971 [TBL] [Abstract][Full Text] [Related]
31. Overview of contrast enhancement with iron oxides. Frija G; Clément O; de Kerviler E Invest Radiol; 1994 Jun; 29 Suppl 2():S75-7. PubMed ID: 7928276 [No Abstract] [Full Text] [Related]
32. Histochemical detection of ultrasmall superparamagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia. Schroeter M; Saleh A; Wiedermann D; Hoehn M; Jander S Magn Reson Med; 2004 Aug; 52(2):403-6. PubMed ID: 15282824 [TBL] [Abstract][Full Text] [Related]
33. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Moore A; Marecos E; Bogdanov A; Weissleder R Radiology; 2000 Feb; 214(2):568-74. PubMed ID: 10671613 [TBL] [Abstract][Full Text] [Related]
35. In vivo detection of developing vessel occlusion in photothrombotic ischemic brain lesions in the rat by iron particle enhanced MRI. Kleinschnitz C; Schütz A; Nölte I; Horn T; Frank M; Solymosi L; Stoll G; Bendszus M J Cereb Blood Flow Metab; 2005 Nov; 25(11):1548-55. PubMed ID: 15917747 [TBL] [Abstract][Full Text] [Related]
36. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017 [TBL] [Abstract][Full Text] [Related]
37. Biodistribution of ultrasmall iron oxide particles in the rat liver. Van Beers BE; Sempoux C; Materne R; Delos M; Smith AM J Magn Reson Imaging; 2001 Apr; 13(4):594-9. PubMed ID: 11276104 [TBL] [Abstract][Full Text] [Related]
38. In vivo fate of superparamagnetic iron oxides during sepsis. Fujii H; Yoshikawa K; Berliner LJ Magn Reson Imaging; 2002 Apr; 20(3):271-6. PubMed ID: 12117609 [TBL] [Abstract][Full Text] [Related]
39. Imaging the fate of implanted bone marrow stromal cells labeled with superparamagnetic nanoparticles. Jendelová P; Herynek V; DeCroos J; Glogarová K; Andersson B; Hájek M; Syková E Magn Reson Med; 2003 Oct; 50(4):767-76. PubMed ID: 14523963 [TBL] [Abstract][Full Text] [Related]
40. Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. Mori K; Yoshioka H; Itai Y; Okamoto Y; Mori H; Takahashi N; Saida Y AJR Am J Roentgenol; 2000 Dec; 175(6):1659-64. PubMed ID: 11090400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]